论文部分内容阅读
伴随卵巢恶性肿瘤的发生和发展,患者体内往往不断产生一些免疫抑制因子(Immunosuppressive factor,简称ISF).这些物质在体内可抑制宿主的细胞免疫反应,在体外可抑制正常人淋巴细胞对植物血凝素(PHA)刺激的反应性,以及效应淋巴细胞对肿瘤靶细胞的细胞毒作用.血清中ISF的水平往往随着肿瘤的切除或病情的缓解而降低,随着肿瘤的复发或病情的恶化再度增高.因此,近年来不少学者对卵巢癌患者血清中的ISF进行了研究,发现肿瘤患者血清对淋巴细胞的抑制绝非某一
With the occurrence and development of malignant ovarian tumors, patients often produce some immunosuppressive factors (ISFs) in vivo, which inhibit the cellular immune response of the host in vivo and inhibit the proliferation of normal human lymphocytes to plant hemagglutination (PHA) stimuli, and cytotoxic effects of effector lymphocytes on tumor target cells.Serum levels of ISF often decrease as tumors are resected or their condition is alleviated, with the recurrence of the tumor or worsening of the condition again Therefore, in recent years, many scholars have studied the ISF in the serum of patients with ovarian cancer and found that the inhibition of lymphocytes in the serum of tumor patients is by no means certain